Xcovery Holdings, Inc.

Xcovery Holdings, Inc. company information, Employees & Contact Information

Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor. Full prescribing information for Ensacove will be posted on Drugs@FDA.

Company Details

Employees
17
Founded
-
Address
168 Se 1st Street, Suite 1100, Miami,florida 33131,united States
Phone
561-835-9356
Email
in****@****ery.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Miami, Florida
Looking for a particular Xcovery Holdings, Inc. employee's phone or email?

Xcovery Holdings, Inc. Questions

News

FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) - Business Wire

FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Business Wire

Xcovery’s Ensacove approved by FDA - The Pharma Letter

Xcovery’s Ensacove approved by FDA The Pharma Letter

Xcovery edges closer to FDA approval for NSCLC ALK inhibitor - Pharmaceutical Technology

Xcovery edges closer to FDA approval for NSCLC ALK inhibitor Pharmaceutical Technology

Xcovery Appoints Giovanni Selvaggi as CEO - citybiz

Xcovery Appoints Giovanni Selvaggi as CEO citybiz

FDA has Approved Ensartinib for ALK-Positive Advanced NSCLC - Oncodaily

FDA has Approved Ensartinib for ALK-Positive Advanced NSCLC Oncodaily

Playing catch-up with Pfizer and Roche, China-made ALK drug clears FDA in lung cancer - Fierce Pharma

Playing catch-up with Pfizer and Roche, China-made ALK drug clears FDA in lung cancer Fierce Pharma

U.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for Ensartinib - Business Wire

U.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for Ensartinib Business Wire

Xcovery to Present at 8th Annual Biotech Showcase™ - PR Newswire

Xcovery to Present at 8th Annual Biotech Showcase™ PR Newswire

Xcovery hires CEO, CMO to lead assault on ALK NSCLC market - Fierce Biotech

Xcovery hires CEO, CMO to lead assault on ALK NSCLC market Fierce Biotech

Xcovery Acquires Majority Controlling Stake in Meryx Pharmaceuticals - citybiz

Xcovery Acquires Majority Controlling Stake in Meryx Pharmaceuticals citybiz

BRAF Mutated Non-small Cell Lung Cancer Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeut - The Globe and Mail

BRAF Mutated Non-small Cell Lung Cancer Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeut The Globe and Mail

Top Xcovery Holdings, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant